All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, March 5, 2021
Home » Blogs » BioWorld MedTech Perspectives » Canada knows innovation

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Canada knows innovation

Nov. 21, 2011
By Amanda Pedersen
No Comments

Flag of Ontario

Hockey isn’t the only thing our northern neighbors do well. Canada – Ontario in particular – knows innovation.

While the U.S. has struggled in recent years to find ways to maintain its leadership position in medical innovation – Ontario has its own strategy that seems to be working out quite well for the Canadian province. More than $13.9 billion in industrial and university-based R&D is performed in Ontario every year.

So, what’s their secret? Ontario offers all the key ingredients for attracting life sciences companies: the right people, the right cost, and a healthy research environment.

Let’s start with the people part of the equation. Ontario has more than 100,000 researchers in its talent pool. Thousands of young researchers and technicians graduate from the province’s 44 universities and colleges every year. Ontario attracts top scientists from around the world with generous funding programs, top-notch lab facilities and the opportunity to work on leading-edge projects in a collaborative environment.

The next ingredient – cost – is particularly impressive, given the troubles U.S. medical device companies are facing with the recent medical device tax. Canada’s R&D tax incentive program is one of the most generous in the world. The after-tax cost of $100 R&D expenditure can be reduced to roughly $56 or even less than $37 for small businesses. A survey of international business costs last year showed that Canada offers the lowest R&D costs among the G7. That same survey reported that the country’s overall business costs were the lowest in the G7 for R&D intensive sectors – including medical devices.

Finally, Ontario encourages business and economic growth by creating the right environment for innovation. The province has partnered with the private sector to invest nearly $3 billion over an eight-year period to support research and commercialization at its universities, hospitals and research institutes. In addition to the generous federal R&D tax program mentioned above, Ontario tops that up with additional tax incentives such as its Ontario Research and Development Tax Credit, the Ontario Innovation Tax Credit, and the Ontario Business-Research Institute tax credit.

As part of the media tour I’ll be participating in today, organized by the Ontario Ministry of Economic Development and Innovation, I will be getting a first-hand look at some of the incredible medical technology being developed here. Check back tomorrow to find out how it went!

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 4.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 4.
  • Celltrion-Regkirona-2-9

    Celltrion wins first conditional Korean approval for COVID-19 antibody Regkirona

    BioWorld
    HONG KONG – Celltrion Inc. has received conditional marketing authorization from the Ministry of Food and Drug Safety (MFDS) for its anti-COVID-19 monoclonal...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing